Integral Diagnostics (IDX) M&A Announcement summary

Deal rationale and strategic fit

• Merger creates a leading diagnostic imaging provider in Australia and New Zealand, combining complementary footprints for greater geographic diversification, scale, and a nationwide network of 155 clinics and over 350 radiologists.

• Aims to deliver best-in-class clinical service, technology, and outcomes for patients, doctors, and referrers, and to attract and retain top radiologists.

• Enhances ability to invest in high-end imaging modalities and expand teleradiology services.

• IDX will acquire 100% of Capitol Health via a scheme of arrangement, creating Australia's largest pure-play publicly listed imaging company and enhancing internal capability for organic growth.

• Provides access to new markets for both parties, including South Australia, Tasmania, Queensland, and New Zealand.

Financial terms and conditions

• Capitol shareholders receive 0.12849 Integral shares per Capitol share, resulting in a 63%/37% ownership split between Integral and Capitol shareholders.

• Implied offer price of $0.3264 per Capitol share, valuing Capitol at $351 million equity and $413 million enterprise value, with a 33% premium to last close.

• Combined pro forma FY23 revenues of $651 million and enterprise value of approximately $1.2 billion.

• Transaction via Scheme of Arrangement, with completion expected in Q4 CY2024.

• Both companies retain the right to pay final dividends for FY24, with mechanisms to preserve the agreed exchange ratio.

Synergies and expected cost savings

• At least $10 million in annual pre-tax net cost synergies anticipated, mainly from consolidation of corporate functions and procurement, with most realized within the first year post-implementation.

• Additional upside from administrative and revenue synergies, including improved billing, claims processes, and doctor productivity gains.

• Synergy estimates account for potential dyssynergies, including remuneration adjustments and ESG roles.

• One-off post-tax integration costs estimated at ~$45 million, including accelerated JV liability payments.

• Expected double-digit pro forma FY25 EPS accretion for shareholders, including cost synergies.